Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

Abstract A89: Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy.

(2014) A. Anichini et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

(2014) Luca Sigalotti et al.   PHARMACOLOGY & THERAPEUTICS

Immune checkpoint blockade in malignant mesothelioma

(2014) Luana Calabrò et al.   OncoImmunology

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

(2013) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Update on the role of ipilimumab in melanoma and first data on new combination therapies

(2013) Michele Maio et al.   CURRENT OPINION IN ONCOLOGY

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications

(2012) S Coral et al.   BRITISH JOURNAL OF CANCER

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma

(2011) Gregory K. Pennock et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

(2010) Luca Sigalotti et al.   Journal of Translational Medicine

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications

(2010) Luana Calabrò et al.   SEMINARS IN ONCOLOGY

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH